Stock listing
KRX:372320 Curocell, Inc. (큐로셀) 주가
Follow Curocell, Inc. into a list and get an email when it puts out news.
Share price · KRX:372320
₩21,200 KRW +50 (+0.2%)
Close on Nov 20, 2026
- Day range
- ₩20,950 – ₩21,500 KRWNov 20, 2026
- Volume
- 12,306 sharesNov 20, 2026
- Market cap
- ₩322.8B KRWAt the close on Nov 20, 2026 · price × 15.23M shares outstanding
- 52-week range
- ₩20,300 – ₩66,000 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩673.0M KRWMedian day 21,372 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:372320 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩21,200 | +50 | +0.2% | ₩21,500 | ₩21,500 | ₩20,950 | 12,306 | |
| ₩21,150 | -250 | -1.2% | ₩21,400 | ₩22,050 | ₩20,900 | 15,845 | |
| ₩21,400 | -100 | -0.5% | ₩21,400 | ₩22,000 | ₩20,950 | 23,329 | |
| ₩21,500 | -800 | -3.6% | ₩22,150 | ₩22,900 | ₩21,200 | 23,021 | |
| ₩22,300 | -450 | -2.0% | ₩22,700 | ₩23,450 | ₩22,200 | 15,938 | |
| ₩22,750 | -750 | -3.2% | ₩22,850 | ₩23,550 | ₩22,400 | 10,703 | |
| ₩23,500 | +1,250 | +5.6% | ₩21,950 | ₩23,600 | ₩21,950 | 24,848 | |
| ₩22,250 | +900 | +4.2% | ₩21,550 | ₩22,500 | ₩21,550 | 13,324 | |
| ₩21,350 | +300 | +1.4% | ₩21,000 | ₩22,300 | ₩20,300 | 37,384 | |
| ₩21,050 | -2,250 | -9.7% | ₩21,500 | ₩22,800 | ₩20,800 | 103,416 | |
| ₩23,300 | +950 | +4.3% | ₩23,550 | ₩24,250 | ₩22,750 | 35,454 | |
| ₩22,350 | -150 | -0.7% | ₩22,750 | ₩23,250 | ₩21,400 | 27,039 | |
| ₩22,500 | -600 | -2.6% | ₩23,400 | ₩23,400 | ₩22,450 | 22,906 | |
| ₩23,100 | +50 | +0.2% | ₩22,400 | ₩23,550 | ₩22,400 | 21,604 | |
| ₩23,050 | -650 | -2.7% | ₩23,000 | ₩23,450 | ₩22,500 | 20,734 | |
| ₩23,700 | -1,300 | -5.2% | ₩25,000 | ₩25,000 | ₩23,550 | 31,735 | |
| ₩25,000 | +600 | +2.5% | ₩24,900 | ₩26,850 | ₩24,750 | 40,616 | |
| ₩24,400 | +1,100 | +4.7% | ₩23,250 | ₩24,900 | ₩23,100 | 27,005 | |
| ₩23,300 | +150 | +0.6% | ₩23,300 | ₩23,300 | ₩22,200 | 19,146 | |
| ₩23,150 | -250 | -1.1% | ₩22,850 | ₩23,200 | ₩22,300 | 21,460 | |
| ₩23,400 | -450 | -1.9% | ₩23,950 | ₩23,950 | ₩23,250 | 18,268 | |
| ₩23,850 | -200 | -0.8% | ₩24,150 | ₩24,600 | ₩23,750 | 16,130 | |
| ₩24,050 | +50 | +0.2% | ₩24,500 | ₩24,750 | ₩23,350 | 29,508 | |
| ₩24,000 | +500 | +2.1% | ₩22,000 | ₩24,300 | ₩22,000 | 16,187 | |
| ₩23,500 | +1,850 | +8.5% | ₩21,800 | ₩23,850 | ₩21,500 | 31,791 | |
| ₩21,650 | -1,100 | -4.8% | ₩22,200 | ₩22,350 | ₩21,250 | 44,040 | |
| ₩22,750 | -400 | -1.7% | ₩23,400 | ₩23,450 | ₩22,450 | 26,750 | |
| ₩23,150 | -850 | -3.5% | ₩23,150 | ₩23,400 | ₩22,300 | 39,507 | |
| ₩24,000 | -2,150 | -8.2% | ₩26,000 | ₩26,000 | ₩23,900 | 61,662 | |
| ₩26,150 | -350 | -1.3% | ₩25,500 | ₩26,800 | ₩24,150 | 72,080 | |
| ₩26,500 | +3,800 | +16.7% | ₩24,000 | ₩26,750 | ₩23,350 | 206,383 | |
| ₩22,700 | -300 | -1.3% | ₩23,000 | ₩23,550 | ₩22,600 | 26,413 | |
| ₩23,000 | +150 | +0.7% | ₩23,000 | ₩23,450 | ₩22,600 | 31,345 | |
| ₩22,850 | +1,200 | +5.5% | ₩21,800 | ₩23,000 | ₩21,550 | 43,361 | |
| ₩21,650 | 0 | 0.0% | ₩22,000 | ₩22,150 | ₩21,400 | 11,252 | |
| ₩21,650 | +50 | +0.2% | ₩21,600 | ₩22,200 | ₩20,850 | 15,695 | |
| ₩21,600 | +400 | +1.9% | ₩21,800 | ₩22,500 | ₩21,350 | 41,818 | |
| ₩21,200 | +300 | +1.4% | ₩21,250 | ₩21,300 | ₩20,800 | 13,937 | |
| ₩20,900 | -150 | -0.7% | ₩21,100 | ₩21,350 | ₩20,850 | 17,546 | |
| ₩21,050 | -400 | -1.9% | ₩21,450 | ₩21,700 | ₩21,000 | 11,160 | |
| ₩21,450 | -50 | -0.2% | ₩21,800 | ₩21,800 | ₩21,150 | 17,156 | |
| ₩21,500 | +50 | +0.2% | ₩21,550 | ₩21,750 | ₩20,850 | 12,971 | |
| ₩21,450 | -600 | -2.7% | ₩22,300 | ₩22,350 | ₩21,250 | 16,700 | |
| ₩22,050 | +50 | +0.2% | ₩22,050 | ₩22,450 | ₩21,650 | 15,565 | |
| ₩22,000 | -850 | -3.7% | ₩22,350 | ₩22,650 | ₩21,650 | 33,757 | |
| ₩22,850 | +50 | +0.2% | ₩22,800 | ₩23,100 | ₩22,450 | 15,986 | |
| ₩22,800 | -1,200 | -5.0% | ₩23,750 | ₩23,750 | ₩22,800 | 42,286 | |
| ₩24,000 | +300 | +1.3% | ₩23,600 | ₩24,000 | ₩23,400 | 14,684 | |
| ₩23,700 | -300 | -1.3% | ₩24,350 | ₩24,350 | ₩23,700 | 21,671 | |
| ₩24,000 | -50 | -0.2% | ₩24,300 | ₩24,300 | ₩23,750 | 12,788 | |
| ₩24,050 | 0 | 0.0% | ₩26,100 | ₩26,100 | ₩23,750 | 49,132 | |
| ₩24,050 | -50 | -0.2% | ₩24,600 | ₩24,600 | ₩23,500 | 17,242 | |
| ₩24,100 | +150 | +0.6% | ₩23,600 | ₩24,150 | ₩23,200 | 13,359 | |
| ₩23,950 | -450 | -1.8% | ₩24,400 | ₩24,450 | ₩23,550 | 17,033 | |
| ₩24,400 | -250 | -1.0% | ₩24,500 | ₩24,550 | ₩23,400 | 17,231 | |
| ₩24,650 | -350 | -1.4% | ₩24,850 | ₩25,300 | ₩24,400 | 10,623 | |
| ₩25,000 | -150 | -0.6% | ₩25,250 | ₩25,550 | ₩24,900 | 18,552 | |
| ₩25,150 | +1,050 | +4.4% | ₩24,450 | ₩25,350 | ₩24,150 | 25,372 | |
| ₩24,100 | +300 | +1.3% | ₩23,500 | ₩24,100 | ₩22,750 | 19,912 | |
| ₩23,800 | +400 | +1.7% | ₩24,350 | ₩24,350 | ₩23,250 | 21,284 | |
| ₩23,400 | -1,700 | -6.8% | ₩24,350 | ₩24,700 | ₩23,250 | 24,929 | |
| ₩25,100 | +400 | +1.6% | ₩26,200 | ₩26,200 | ₩24,800 | 18,122 |
- Ticker
- KRX:372320
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- KRX
- Currency
- KRW
Latest news
Curocell, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 1 in all · newest Oct 13, 2025 · oldest 2025
Valuation
Price/book 4.5× against a median of 1.8×: 8th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₩257.6B KRW
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 4.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.2×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Curocell, Inc. · KRX:372320 | US$241.3M | US$192.5M | n/a | n/a | n/a | 4.5× | n/a | 0.2× | n/a |
| Editas Medicine, Inc. · NASDAQ:EDIT | US$253.1M | US$119.7M | n/a | 2.4× | n/a | 3.0× | −144.9% | 0.7× | 2.22 |
| Q32 Bio Inc. · NASDAQ:QTTB | US$249.6M | −US$35.66M | 7.7× | −0.7× | −1.9× | 0.9× | 59.8% | 0.0× | 0.59 |
| Turn Therapeutics Inc. · NASDAQ:TTRX | US$247.5M | US$244.2M | n/a | n/a | n/a | 43.5× | n/a | 1.1× | 1.54 |
| Mabpharm Limited · HKEX:2181 | US$247.3M | US$279.4M | 29.7× | 3.0× | 28.9× | 8.5× | 8.8% | 1.6× | n/a |
| Lexeo Therapeutics, Inc. · NASDAQ:LXEO | US$245.1M | US$56.52M | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.62 |
| Shandong Boan Biotechnology Company., Limited. Class H · HKEX:6955 | US$242.7M | US$93.26M | 227× | 0.8× | 4.7× | 0.6× | 0.9% | 0.0× | n/a |
| Clinuvel Pharmaceuticals Limited · ASX:CUV | US$238.9M | US$73.38M | 10.3× | 1.1× | 2.6× | 1.3× | 36.0% | 0.0× | n/a |
| CAMP4 Therapeutics Corporation · NASDAQ:CAMP | US$237.8M | US$119.8M | n/a | 22.5× | n/a | 2.2× | n/a | 0.1× | 1.70 |
| Valerio Therapeutics · EURONEXT:ALVIO | US$228.9M | US$242.3M | n/a | 85.8× | 50.8× | n/a | −190.4% | n/a | n/a |
| Scribe Therapeutics Inc. · NASDAQ:SCTX | US$228.5M | US$59.42M | n/a | 1.2× | n/a | 1.8× | −42.6% | 0.0× | n/a |
| Median of the others | US$243.9M | US$106.5M | 20.0× | 1.8× | 4.7× | 1.8× | 0.9% | 0.0× | 1.62 |
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | ||
| Cost of revenue | 0 | 0 | 0 | ||
| Gross profit | 0 | 0 | 0 | ||
| Research and development | 31.3B | 31.9B | 27.2B | 19.7B | 13.2B |
| Selling, general and administrative | 1.04B | 4.66B | 3.85B | 1.72B | 464.0M |
| Operating income | -36.3B | -36.6B | -31.1B | -21.4B | -15.3B |
| Depreciation and amortization | 6.12B | 6.32B | 4.70B | 1.82B | 1.71B |
| EBITDA | -30.2B | -30.3B | -26.4B | -19.6B | -13.6B |
| Interest expense | 4.54B | 2.60B | 2.43B | 207.3M | 195.2M |
| Income before tax | -46.3B | -38.2B | -29.7B | -38.9B | -53.6B |
| Net income | -46.3B | -38.2B | -29.6B | -38.9B | -53.6B |
| Earnings per share, basic | -3,073.95 | -2,693.04 | -2,172.59 | -2,856.52 | -3,935.70 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | 10.2B | 4.58B | 9.92B | 6.63B | 42.6B |
| Short-term investments | 14.0B | 5.00B | 30.0B | 500.0M | 19.8B |
| Receivables | 3.32M | 91.3M | 372.8M | ||
| Inventory | 1.68B | ||||
| Current assets | 32.3B | 13.0B | 42.8B | 41.4B | 64.2B |
| Property, plant and equipment | 55.4B | 61.2B | 46.1B | ||
| Total assets | 109.7B | 72.0B | 105.0B | 88.0B | 82.2B |
| Current liabilities | 97.0B | 38.8B | 3.27B | 106.6B | 84.8B |
| Long-term debt | 0 | 39.6B | 26.1B | 6.61B | |
| Total liabilities | 104.7B | 42.6B | 45.9B | 135.6B | 94.4B |
| Shareholders' equity | 5.03B | 29.5B | 59.1B | -47.6B | -12.2B |
| Shares outstanding | 15.1M | 14.2M | 13.6M | 13.6M | 13.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash from operations | -30.0B | -28.4B | -25.3B | -14.4B | -11.5B |
| Capital spending | -2.22B | -1.21B | -21.7B | -27.9B | -9.30B |
| Free cash flow | -32.2B | -29.6B | -46.9B | -42.3B | -20.8B |
| Cash from investing | 22.0B | -21.1B | -40.7B | ||
| Cash from financing | 1.04B | 49.7B | 19.1B | ||
| Share buybacks | 1.56B | 32.2B | 54.1M | ||
| Change in cash | 5.58B | -5.34B | 3.29B | -36.0B | 39.2B |
Cap table
Built by 6ix from Curocell, Inc.’s releases
- Common shares
- 15,225,918
- Fully diluted
- 15,225,918
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 15,225,918 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 15,225,918 |
Log in to ask 6ix AI your own questions about Curocell, Inc.